The CKD indication is expected to be a meaningful growth driver for FUROSCIX. The company has already received early prescriptions from nephrologists and is preparing for a full-scale launch in ...

which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric ...

However, what many people don’t realize is that these beverages can have serious consequences for kidney health. Energy ...

ProKidney Corp. reported Friday a $61.2 million loss in fiscal 2024 as the biotechnology company resumed production and ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 ...

The famous St. Anthony’s Church feast this year was held on 14 and 15 March. St. Anthony, as per Catholic belief, gives ...

MRCP(UK), FRCP(Edin), FRCP(Lond), FRCPCH(UK), FSLCPaed, FCCP, Hony. FRCPCH(UK), Hony. FCGP(SL) Specialist Consultant ...

Over my forty years or so in and around dealing rooms and financial markets, I have heard many theories as to how to approach that problem and have settled on a process that has worked for me ...

Objective: To explore the impact of statin use on cognition. Data Sources: A literature search was performed using MEDLINE (1950-November 2011), EMBASE (1980-November 2011), and the Cochrane ...